A sclerostin-targeting polydopamine nanoplatform promotes osteogenesis and attenuates ovariectomy-induced bone loss by reducing ferroptosis-like injury
Osteoporosis is characterized by reduced bone mass, disrupted trabecular microarchitecture and increased fracture risk. Although sclerostin inhibition is an established bone-anabolic strategy, systemic blockade may raise safety concerns and conventional drug delivery to bone remains inefficient. Here, we developed a sclerostin-targeting, lipid-coated polydopamine nanoplatform loaded with N-oleoyl-L-serine (OS) and modified with the sclerostin-targeting aptamer Aptscl56 (PDA@NLipo-Aptscl56). The formulation showed a uniform nanoscale morphology, negative surface charge, favorable colloidal stability, efficient N-oleoyl-L-serine loading, measurable Aptscl56 conjugation and sustained release behavior. In primary bone marrow mesenchymal stem cells (BMSCs), PDA@NLipo-Aptscl56 exhibited good biocompatibility and enhanced osteogenic differentiation, as indicated by increased alkaline phosphatase activity, matrix mineralization and upregulation of osteogenic markers including ALP, RUNX2, OSX and OPN. Single-component controls demonstrated that PDA alone and free Aptscl56 had limited osteogenic effects, whereas OS alone and non-targeted PDA@NLipo-PEG produced moderate effects; the complete PDA@NLipo-Aptscl56 formulation exerted the strongest osteogenic activity. In ovariectomized mice, PDA@NLipo-Aptscl56 improved femoral trabecular bone parameters and histological mineralization. Proteomic analysis suggested treatment-associated changes in ferroptosis- and mitochondrial respiratory-chain-related proteins, with Uqcrfs1 emerging as a high-degree candidate protein within a mitochondrial protein interaction network. Mechanistically, PDA@NLipo-Aptscl56 reduced ferroptosis-like injury in OVX bone tissue and RSL3-treated osteoblasts, as reflected by restored GPX4/FTH1/FTL expression, reduced ACSL4 expression, and decreased Fe 2+ and 4-HNE levels. Uqcrfs1 overexpression partially attenuated these protective effects, supporting its involvement in the anti-ferroptotic response to PDA@NLipo-Aptscl56. Representative fluorescence biodistribution and safety analyses further supported the bone-targeting tendency and preliminary biosafety of the formulation. These findings indicate that PDA@NLipo-Aptscl56 is a promising bone-targeted nanoplatform for promoting osteogenesis and attenuating OVX-induced bone loss, partly through suppression of ferroptosis-like oxidative injury.
Authors
- 周孜辉
- Dengshuo Sun
- Jian Chen
- Shengyang Ge
Institutions
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Ruijin Hospital (CN)
- Tongren Hospital (CN)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1038/s41598-026-80076-1
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00